TEI 9647

a 1alpha,25-dihydroxyvitamin D3 antagonist; TEI-9647 is the (23S)-isomer, and TEI-9648 is the (23R)-isomer; structure in first source

Also Known As:

25-dehydro-1-hydroxyvitamin D(3)-26,23-lactone; 25-dehydro-1-hydroxyvitamin D3-26,23-lactone; TEI 9648; TEI-9647; TEI-9648

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Ishizuka, Seiichi: 3 articles (05/2005 - 05/2004)
2.	Miura, Daishiro: 2 articles (05/2005 - 05/2004)
3.	Takenouchi, Kazuya: 2 articles (05/2005 - 05/2004)
4.	Cornish, Jillian: 2 articles (04/2005 - 05/2004)
5.	Cundy, Tim: 2 articles (04/2005 - 05/2004)
6.	Kurihara, Noriyoshi: 2 articles (04/2005 - 05/2004)
7.	Reddy, Sakamuri V: 2 articles (04/2005 - 05/2004)
8.	Roodman, G David: 2 articles (04/2005 - 05/2004)
9.	Honzawa, Shinobu: 1 article (01/2006)
10.	Kittaka, Atsushi: 1 article (01/2006)

Related Diseases

1.	Bone Resorption 04/01/2005 - "These results demonstrate that TEI-9647 can suppress the excessive bone resorption and OCL formation seen in marrow cultures from patients with PD." 04/01/2005 - "Moreover, bone resorption by OCLs derived from MVNP-transduced CFU-GM treated with 10(-9) m 1alpha,25-(OH)(2)D(3) was dose-dependently inhibited by TEI-9647 (10(-9) m to 10(-6) m). " 05/01/2004 - "These results suggest that TEI-9647 acts directly on osteoclast precursors and osteoclasts, and that TEI-9647 may be a novel agent to suppress the excessive bone resorption and osteoclast formation in patients with Paget's disease." 05/01/2004 - "Moreover, TEI-9647 dose-dependently inhibited bone resorption induced by 10(-9)M 1alpha,25-(OH)(2)D(3) by osteoclasts produced by RANKL and M-CSF treatment of measles virus nucleocapsid gene transduced bone marrow cells. "
2.	Osteosarcoma (Osteogenic Sarcoma) 05/01/2005 - "We tested TEI-9647 on 1alpha,25(OH)(2)D(3) transactivation using SaOS-2 cells (human osteosarcoma) or ROS 24/1 cells (rat osteosarcoma) cotransfected with human or rodent VDR and a reporter. "
3.	Psoriasis (Pustulosis Palmaris et Plantaris) 01/01/2006 - "The structure-activity relationships of 1alpha,25-dihydroxyvitamin D3 on simultaneous modification at both C2alpha and CD-ring side chain, including 20-epimerization, double side chain (gemini), and vitamin D receptor (VDR) antagonists TEI-9647 and TEI-9648 lactone rings, and also on simultaneous modifications at both C2 and C10 positions, i.e., C2 modified active 19-norvitamin D3, have been studied in our laboratory to find new seeds of B-seco-steroidal medicine for treating bone diseases, psoriasis, secondary hyperparathyroidism, and certain kinds of cancers. "
4.	Neoplasms (Cancer) 01/01/2006 - "The structure-activity relationships of 1alpha,25-dihydroxyvitamin D3 on simultaneous modification at both C2alpha and CD-ring side chain, including 20-epimerization, double side chain (gemini), and vitamin D receptor (VDR) antagonists TEI-9647 and TEI-9648 lactone rings, and also on simultaneous modifications at both C2 and C10 positions, i.e., C2 modified active 19-norvitamin D3, have been studied in our laboratory to find new seeds of B-seco-steroidal medicine for treating bone diseases, psoriasis, secondary hyperparathyroidism, and certain kinds of cancers. "
5.	Secondary Hyperparathyroidism 01/01/2006 - "The structure-activity relationships of 1alpha,25-dihydroxyvitamin D3 on simultaneous modification at both C2alpha and CD-ring side chain, including 20-epimerization, double side chain (gemini), and vitamin D receptor (VDR) antagonists TEI-9647 and TEI-9648 lactone rings, and also on simultaneous modifications at both C2 and C10 positions, i.e., C2 modified active 19-norvitamin D3, have been studied in our laboratory to find new seeds of B-seco-steroidal medicine for treating bone diseases, psoriasis, secondary hyperparathyroidism, and certain kinds of cancers. "

Related Drugs and Biologics

1.	TEI 9647
2.	Calcitriol Receptors (Calcitriol Receptor)
3.	Macrophage Colony-Stimulating Factor
4.	Lactones
5.	hydroxide ion